Anthony B. Costales, MD, on Advanced Ovarian Cancer: Predicting the Benefits of Minimally Invasive Surgery
SGO 2021 Virtual Annual Meeting on Womens Cancer
Anthony B. Costales, MD, of the Baylor College of Medicine, discusses results from the MIID-SOC trial, which explored the question of whether laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy is feasible, safe, and provides similar outcomes as open surgery.
The ASCO Post Staff
Morcos N. Nakhla, MS, a second-year student at the David Geffen School of Medicine at UCLA, discusses data showing that a higher surgical volume is associated with better outcomes for frail patients undergoing surgery for ovarian cancer. Over the 12-year study period, mortality decreased for all women with ovarian cancer, despite a concurrent increase in frail patients (ID #10209).
The ASCO Post Staff
Lauren Thomaier, MD, of the University of Minnesota, discusses the genetic variants found to be associated with an increase in chemotherapy-induced neuropathy symptoms in a cohort of gynecologic cancer survivors. Combining these variants with clinical characteristics may provide an important treatment tool (ID# 10253).
The ASCO Post Staff
Amir A. Jazaeri, MD, of The University of Texas MD Anderson Cancer Center, discusses data on the safety and efficacy of adoptive cell transfer using autologous tumor-infiltrating lymphocytes (LN-145) to treat patients with recurrent, metastatic, or persistent cervical carcinoma whose tumors have progressed on prior systemic therapy (ID # 10224).
The ASCO Post Staff
Hyun C. Chung, MD, of Yonsei Cancer Center and Yonsei University College of Medicine, discusses phase II findings from the KEYNOTE-158 study, which support the use of pembrolizumab for patients with recurrent or metastatic cervical cancer that has progressed on or after chemotherapy and whose tumors express PD-L1.
The ASCO Post Staff
Brian M. Slomovitz, MD, of Florida International University, describes how emphasizing diversity and shifting away from clinical trials at universities helped The GOG Foundation, Inc., increase patient accrual by 50% in 2020 (ID # 10215).
